RX TRANSPARENCY (SB 5586)
Requires drug manufacturers to report prescription drug pricing data to OFM, allowing policy-makers better tools to manage one of the largest cost-drivers of health care.
1/12/18 The Senate Health and Long-Term Care Committee holds a hearing on one of our priority issues, prescription drug cost transparency, in this case SB 5586. A House version, 2SHB 1541, is awaiting a vote of the full House.